Company intelligence / Profile preview

Fiave

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Fiave is an early-stage biotechnology company focused on developing novel therapeutic approaches for inflammatory and autoimmune diseases. The company operates primarily in stealth mode, leveraging a proprietary platform to identify and target specific pathways involved in immune system dysregulation. Fiave aims to address significant unmet medical needs by creating precision medicines that offer improved efficacy and safety profiles compared to current standards of care. The leadership team consists of experienced industry veterans with a track record of successful drug development in the immunology space.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Fiave.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fiave.

Explore the full profile